Form 8-K - Current report:
SEC Accession No. 0001193125-25-163400
Filing Date
2025-07-23
Accepted
2025-07-23 16:01:13
Documents
12
Period of Report
2025-07-23
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d931384d8k.htm   iXBRL 8-K 27934
  Complete submission text file 0001193125-25-163400.txt   141559

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA rntx-20250723.xsd EX-101.SCH 2856
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE rntx-20250723_lab.xml EX-101.LAB 17994
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rntx-20250723_pre.xml EX-101.PRE 11265
15 EXTRACTED XBRL INSTANCE DOCUMENT d931384d8k_htm.xml XML 3678
Mailing Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758
Business Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758 7378021989
Rein Therapeutics, Inc. (Filer) CIK: 0001420565 (see all company filings)

EIN.: 134196017 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38130 | Film No.: 251143064
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)